M. Dubosq

发表

Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.

E. Blyth, D. Gottlieb, K. Micklethwaite, 2015, Cytotherapy.

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.

P. Shaw, A. Yong, E. Blyth, 2017, Blood advances.

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-speci ﬁ c T cells

P. Shaw, A. Yong, E. Blyth, 2017 .

Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant

F. Luciani, B. Gloss, H. McGuire, 2021, Clinical & translational immunology.

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.

K. Byth, P. Shaw, E. Blyth, 2013, Blood.

TRANSPLANTATION Donor-derived CMV-speci ﬁ c T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

K. Byth, Peter Shaw, E. Blyth, 2013 .

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.